MX9706739A - Metodo de fabricacion de un agente terapeutico para la regeneracion de oligodendrocitos. - Google Patents

Metodo de fabricacion de un agente terapeutico para la regeneracion de oligodendrocitos.

Info

Publication number
MX9706739A
MX9706739A MX9706739A MX9706739A MX9706739A MX 9706739 A MX9706739 A MX 9706739A MX 9706739 A MX9706739 A MX 9706739A MX 9706739 A MX9706739 A MX 9706739A MX 9706739 A MX9706739 A MX 9706739A
Authority
MX
Mexico
Prior art keywords
oligodendrocytes
regeneration
therapeutic agent
preparation
treatment
Prior art date
Application number
MX9706739A
Other languages
English (en)
Inventor
Juergen Unger
Ilse Bartke
Kurt Naujoks
Yorn Schmidt
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of MX9706739A publication Critical patent/MX9706739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Con el método de preparacion de un agente terapéutico para el tratamiento de esclerosis multiple, en donde el factor de crecimiento del nervio beta humano (NGF) es contenido en una formulacion farmacéuticamente aceptable para la administracion en una dosis entre 0.05 æg/Kg de peso corporal en 1 a 10 inyecciones en un intervalo de 1 a 21 días, la regeneracion de oligodendrocitos, especialmente para el tratamiento de esclerosis multiple, se mejora y la remielinacion se acelera.
MX9706739A 1995-03-10 1996-03-08 Metodo de fabricacion de un agente terapeutico para la regeneracion de oligodendrocitos. MX9706739A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95103458A EP0731108A1 (en) 1995-03-10 1995-03-10 Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
PCT/EP1996/000992 WO1996028180A1 (en) 1995-03-10 1996-03-08 Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes

Publications (1)

Publication Number Publication Date
MX9706739A true MX9706739A (es) 1997-11-29

Family

ID=8219056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706739A MX9706739A (es) 1995-03-10 1996-03-08 Metodo de fabricacion de un agente terapeutico para la regeneracion de oligodendrocitos.

Country Status (12)

Country Link
US (1) US6268340B1 (es)
EP (2) EP0731108A1 (es)
JP (1) JPH10504320A (es)
AT (1) ATE241381T1 (es)
AU (1) AU5103696A (es)
CA (1) CA2214999A1 (es)
DE (1) DE69628417T2 (es)
DK (1) DK0814828T3 (es)
ES (1) ES2194978T3 (es)
MX (1) MX9706739A (es)
PT (1) PT814828E (es)
WO (1) WO1996028180A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227900B1 (en) * 1985-12-02 1993-03-31 International Business Machines Corporation Three address instruction data processing apparatus
AU7214998A (en) * 1997-04-11 1998-11-11 Regents Of The University Of California, The Ngf for the prevention of demyelination in the nervous system
WO1998056403A1 (en) * 1997-06-13 1998-12-17 Roche Diagnostics Gmbh Improvement of the regeneration of myelin sheaths
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
JP2002204691A (ja) * 2001-01-09 2002-07-23 Japan Science & Technology Corp 神経細胞再髄鞘化のための移植用細胞キット
GB0119435D0 (en) 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5885584A (en) * 1991-08-05 1999-03-23 Boehringer Mannheim Gmbh Regeneration of oligodendrocytes
DE4125933A1 (de) 1991-08-05 1993-02-11 Max Planck Gesellschaft Verbesserung der regeneration von oligodendrocyten

Also Published As

Publication number Publication date
DE69628417D1 (de) 2003-07-03
DK0814828T3 (da) 2003-09-29
PT814828E (pt) 2003-10-31
EP0814828B1 (en) 2003-05-28
WO1996028180A1 (en) 1996-09-19
JPH10504320A (ja) 1998-04-28
DE69628417T2 (de) 2004-03-18
EP0814828A1 (en) 1998-01-07
ATE241381T1 (de) 2003-06-15
US6268340B1 (en) 2001-07-31
ES2194978T3 (es) 2003-12-01
AU5103696A (en) 1996-10-02
EP0731108A1 (en) 1996-09-11
CA2214999A1 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
NZ500763A (en) Use of PEG 12000-IFN alpha in treating viral infection
HU9303748D0 (en) Composition of l-dopa-esters
HUT62798A (en) Process for producing pharmaceutical composition with slimming activity
AP1529A (en) Therapeutic formulation for administering tolterodine with controlled release.
CA2041579A1 (en) Dosage form
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
EP0416454A3 (en) Method of and apparatus for administering medicament to a patient
HU883981D0 (en) Process for the production of medical preparations with antiviral or antibacterial effect
EP0289186A3 (en) Process for increasing the growth rate and enhancing the feed efficiency of meat producing livestock
MX9706739A (es) Metodo de fabricacion de un agente terapeutico para la regeneracion de oligodendrocitos.
CA2139385A1 (en) Products containing g-csf and tnf binding protein
MY124465A (en) Reduction of infarct volume using citicoline
EP0414772A4 (en) Method for treating acne
WO1997029745B1 (en) Zwitterionic compositions and methods as biological response modifiers
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
JO1589B1 (en) Ketones (quaternary hydroimidazo (4.1) benzo-diazepine-2) anti-viral
EP0393707A3 (en) Bioactive compounds associated with liposomes and their use in pharmaceutical preparations
EP0175440A3 (en) Method of treating migraine headaches
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
JPS6483020A (en) Medicinal composition for preventing or treating aids
BG60164B2 (bg) Метод за получаване на стереоизомери
MD197G2 (ro) Preparat şi procedeu de tratare a hipogalactiei
IL107818A (en) Pharmaceutical compositions for treating viral infections by conjunctive therapy with acylovir-like compounds and a 2'-(halo) methylene nucleoside analog
Adam et al. Diffusion of cefamandole into the heart muscle tissue
UA10219A (uk) Спосіб лікування туберкульозу легень

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: KURT NAUJOKS

MM Annulment or lapse due to non-payment of fees